Fair Value Calculator Fair Value Calculator
EN DE

9996 (9996) Fair Value & Analysis

Healthcare · Market cap HK$2.7B

9 9996 9996 · HK
PriceHK$4.10
Fair ValueHK$2.13
Upside-48.0%
Quality42/100
Watch 9996 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$1.59 – HK$3.18

Fair value as of: Jul 3, 2026

From 1 valuation models · updated today

Share price −13.1% over the past month.

Price vs Fair Value (12 months)

HK$9.26 HK$3.77 Fair Value HK$2.13 Jun 2025 Jul 2026

12‑month range HK$3.77 – HK$9.26 · fair‑value band HK$1.59 – HK$3.18 · the HK$4.10 price screens above the HK$2.13 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

9996 (9996) currently trades at HK$4.10, while our model-based Fair Value estimate is HK$2.13 — implying the stock looks roughly 48.0% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 9996 generated revenue of HK$713M at a net margin of -28.5%. Revenue grew 14.4% year over year. It earns a return on equity of -10.7%. The balance sheet holds a net cash position of HK$153M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$713M
Revenue growth (YoY) +14.4%
Net margin -28.5%
Return on equity -10.7%
Free cash flow −HK$325M FY2025
Operating margin -36.2%
More key figures
EPS (TTM) HK$-0.1000
Net cash HK$153M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

9996 reported revenue of HK$713M in FY2025 versus HK$137M in FY2021, a compound +51.2%/yr. Reported net income was −HK$203M in FY2025.

Revenue +51.2%/yr
FY21 HK$137M
FY22 HK$251M
FY23 HK$441M
FY24 HK$615M
FY25 HK$713M
Net income
FY21 −HK$574M
FY22 −HK$408M
FY23 −HK$393M
FY24 −HK$227M
FY25 −HK$203M

Is 9996 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock Price Fair Value vs Fair Value
ABT ABT 1,600 MXN 1,231 MXN -23%
Abbott Laboratories, ABTT34 R$39.41 R$30.42 -23%
Stryker Corporation S1YK34 R$79.18 R$43.78 -45%
Medtronic plc MDT $81.67 $60.02 -27%
Boston Scientific Corporation B1SX34 R$229.30 R$43.33 -81%
Edwards Lifesciences Corporation EW $85.98 $41.02 -52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 9996 (9996) undervalued?
As of Jul 3, 2026, our model estimates a fair value of HK$2.13 versus a price of HK$4.10 — about −48% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 9996?
Our model-based fair value for 9996 is HK$2.13 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$4.10.
What is the quality score of 9996?
9996 has a Quality Score of 42/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 9996 (9996)?
9996 reported trailing-twelve-month revenue of about HK$713M (latest available figure, as of Jul 3, 2026).
What is the net profit margin of 9996?
The net profit margin of 9996 is about -28.5%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.